Evidence map›Paper›PMID 42788099›Full record

ArticleVaccine: X2026

Timeliness of measles vaccination in selected districts of Oromia Region, Ethiopia - 2021.

Monica P Shah, Abyot Bekele Woyessa, Almea M Matanock, Binyam Moges Azmeraye, Leuel Lisanwork, Getnet Yimer, Shu-Hua Wang, Xueliang Pan, Paulos Samuel, Bekana Tolera and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine: X, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Monica P ShahGlobal Immunization Division, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Abyot Bekele WoyessaCDC Foundation Contract Consultant Assigned to Oromia Health Bureau, Addis Ababa, Ethiopia.
Almea M MatanockGlobal Immunization Division, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Binyam Moges AzmerayeGlobal One Health Initiative, College of Medicine, The Ohio State University, Addis Ababa, Ethiopia.
Leuel LisanworkGlobal One Health Initiative, College of Medicine, The Ohio State University, Addis Ababa, Ethiopia.
Getnet YimerDepartment of Genetics and Center for Global Genomics and Health Equity, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Shu-Hua WangDivision of Infectious Diseases, Department of Medicine, The Ohio State University Global One Health initiative, College of Medicine, Ohio State University, Columbus, OH, USA.
Xueliang PanDivision of Infectious Diseases, Department of Medicine, The Ohio State University Global One Health initiative, College of Medicine, Ohio State University, Columbus, OH, USA.
Paulos SamuelOromia Health Bureau, Addis Ababa, Ethiopia.
Bekana ToleraOromia Health Bureau, Addis Ababa, Ethiopia.
Birhanu Kenate SoriOromia Health Bureau, Addis Ababa, Ethiopia.
Abebe BekeleOromia Health Bureau, Addis Ababa, Ethiopia.
Tesfaye DetiCDC Foundation Contract Consultant Assigned to Oromia Health Bureau, Addis Ababa, Ethiopia.
Getachew WakoUNICEF Ethiopia, Addis Ababa, Ethiopia.
Amsalu ShiferawUNICEF Ethiopia, Addis Ababa, Ethiopia.
Yohannes Lakew TeferaMinistry of Health of Ethiopia, Addis Ababa, Ethiopia.
Melkamu Ayalew KokebieMinistry of Health of Ethiopia, Addis Ababa, Ethiopia.
Tatek Bogale AnbessieAfrican Field Epidemiology Network, Addis Ababa, Ethiopia.
Habtamu Teklie WubieEthiopian Public Health Institute, Addis Ababa, Ethiopia.
Qian AnGlobal Immunization Division, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Aaron WallaceGlobal Immunization Division, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Ciara E SugermanGlobal Immunization Division, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Funding

Intramural CDC HHS CC999999
6 · The paper itself

Abstract

Background: Delays in vaccination with the first/second dose of measles-containing vaccine (MCV1, MCV2) increases risk of measles transmission. MCV2 was added to Ethiopia's routine immunization schedule in 2019, administered at age 15 months. We describe age at measles vaccination and characteristics associated with timely vaccination following MCV2 introduction. Methods: A secondary analysis from a 2021 cross-sectional household survey of children aged 12-35 months in Oromia, Ethiopia was conducted. MCV vaccination status and age at vaccination were determined from the child's vaccination card. The cumulative card-confirmed vaccination coverage of MCV1 and MCV2 (among children 24-35 months) by age at vaccination was estimated. Among children who received MCV, vaccination timing was classified as early (MCV1: <9 months; MCV2: <15 months), timely (MCV1: 9 to <10 months; MCV2: 15 to <16 months), or delayed (MCV1: ≥10 months; MCV2: ≥16 months). Characteristics associated with timely MCV1 vaccination were analyzed using multivariate logistic regression, with urban/rural stratification. Results: Overall, 651 children aged 12-35 months (MCV1) and a subset of 270 children aged 24-35 months (MCV2) were analyzed. Cumulative MCV1 coverage was 59.9% by age 9 months and 76.3% by age 12 months, and MCV2 was 33.0% by age 15 months and 44.8% by age 24 months. MCV coverage was generally higher in urban compared to rural areas. Among vaccinated children, the proportion receiving early, timely, and delayed doses was 30.1%, 44.5%, and 25.3% for MCV1, and 28.6%, 41.2%, and 30.3% for MCV2, respectively. Characteristics associated with timely MCV1 vaccination differed in urban and rural areas, but common themes included increased caregiver immunization awareness and service delivery aspects. Conclusions: Although most children who received MCV1 were vaccinated by 12 months, many received delayed doses. MCV2 coverage was low, irrespective of vaccination timing. Findings highlight the importance of routine catch-up vaccination policies and guidance, and the need for tailored strategies in urban and rural settings to improve MCV coverage and timely vaccination.

Indexed as

Immunization coverageMeaslesMeasles-containing vaccineSecond year of lifeVaccination timing

Identifiers

PMID42788099
PMCPMC13606021

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.